• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers develop micropump for patients with glaucoma

March 3, 2017 By Sarah Faulkner

Researchers develop micropump for patients with glaucomaResearchers from the University of Southern California’s Roski Eye Institute developed a micropump that can be implanted directly into the eye and deliver a predetermined dose of the diabetic macular edema drug ranibizumab.

Current treatments for glaucoma are traditionally delivered using eye drops. But studies show that some patients stop taking their prescription glaucoma eye drops after 1 year, according to the team of researchers. Patients can be uncomfortable using the eye drops or they forget to consistently take their prescribed medication.

To address the treatment’s noncompliance issue, the researchers developed a micropump that includes a reservoir for medication. Dosage and frequency can be controlled using a wirelessly-connected device, according to the team.

The scientists evaluated their micropump in 11 patients with diabetic macular edema and visual acuity of 20/40 eyesight or worse. Following implantation, the device was programmed to deliver a predetermined dose of ranibizumab.

The study participants received ophthalmic exams as well as optical coherence tomography every 2 weeks for 90 days.

The team reported that they conducted 7 successful trials and 4 unsuccessful trials. In successful trials, the micropump delivered the medication dose within 20% of the target amount and participants saw improved visual acuity and retinal thickness. But in the other 4 trials, dose delivery was too slow or inhibited due to a damaged device.

There were no serious adverse effects and all of the participants healed normally, according to the researchers. The team reported that no one complained that they could feel the pump in their eye.

The pump is being commercially developed by Replenish Inc.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Research & Development Tagged With: Replenish Inc.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS